Your assay choice matters
For every 10 cancer patients treated, an average of only half will benefit. For some, the treatment won’t have any effect; others may suffer from serious side effects.1 In collaboration with leading pharmaceutical companies, we identify and develop innovative predictive diagnostics to target those patients who are more likely to respond to specific therapies.
The global partner of choice for tissue-based companion diagnostics, we help to advance Personalized Healthcare by delivering diagnostic confidence through a broad menu of high medical value predictive assays. Our standardized, fully-automated and easy-to-use solutions enable rapid turnaround time, empowering physicians to make the right patient decisions more quickly.
VENTANA ALK (D5F3) CDx Assay*
Identifying ALK+ NSCLC patients for targeted treatment
The VENTANA ALK (D5F3) CDx Assay* empowers your lab to provide timely results using fully automated, ready-to-use reagents.
We see an enormous potential and huge opportunities in PHC. Targeted therapies and diagnostic tests that help to improve medical decision making not only offer clinical benefits for patients but are also attractive through health economic benefits to regulatory authorities and payers.
— Severin Schwan, CEO Roche
The VENTANA PD-L1 portfolio
VENTANA PD-L1 assays generate results you can trust, so that you can make timely diagnostic decisions and therapeutic choices.
As a cancer survivor, if I hadn’t had this individual therapy, my outcome might be totally different than what it is now.
— Nancy, breast cancer patient tested with Roche companion diagnostic assay
*VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody in countries outside the US
- Source: Roche Personalized Healthcare brochure, 2011
Learn more about Personalized Healthcare (PHC):
Explore by disease state: http://www.ventana.com/diseasestate